Merck & Co. (MRK) Q1 2026 Earnings
Merck & Co. reported Q1 2026 revenue of $16.3B (+4.9% YoY), beat analyst consensus of $15.8B by $439.7M. Diluted EPS came in at $-1.28, beat the $-1.47 consensus by $0.19. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Financial Snapshot
Trailing eight quarters through Q1 2026 — latest period from 8-K press release; updates when 10-Q/10-K is filed
Q1 2026 Earnings FAQ
Common questions about Merck & Co.'s Q1 2026 earnings report.
Merck & Co. (MRK) reported Q1 2026 earnings on April 30, 2026 before market open.
Merck & Co. reported revenue of $16.3B and diluted EPS of $-1.28 for Q1 2026.
Revenue beat the consensus estimate of $15.8B by $439.7M. EPS beat the consensus estimate of $-1.47 by $0.19.
Compared to the same quarter a year prior, revenue grew 4.9% from $15.5B a year earlier.
You can read the 8-K earnings release (0001104659-26-052081) directly on SEC EDGAR. The filing index links above go to sec.gov.